The medical device firm reaffirms its $882M revenue outlook while raising profitability guidance amid double-digit surgical volume gains.
Alphatec Holdings raised its 2026 adjusted EBITDA guidance to $140M, up from prior expectations, while maintaining its revenue outlook of approximately $882M. The update follows a strong Q2 performance, with revenue reaching $214 million.
Surgical revenue climbed 17% in the quarter, driven by a 20% increase in cases and a 24% rise in active surgeons. The company attributed the growth to expanding adoption of its spinal surgery solutions.
Management highlighted continued momentum in profitability metrics, though no immediate market reaction was disclosed in the earnings call summary.